NEJM Review Time

For year-over-year citation data, see the NEJM citation metrics page.

NEJM was down from 96.2 in 2023 to 78.5 in 2024 as the pandemic citation surge continued to normalize. That matters mostly as context: the journal is still operating at an elite clinical-medicine tier, and the practice-changing bar has not softened just because the citation metrics came back toward baseline.

Source: NEJM publication process and author-center pages, accessed 2026-10-08. NEJM does not publish the stage timings marked above as unpublished.

NEJM says it receives over 5,000 original research submissions each year and that about 5% achieve publication. The math alone explains the rejection rate. But the editorial criteria are also extremely specific:

The paper must present evidence that could change what a practicing clinician does tomorrow. Not "eventually," not "in principle." The editorial question is: does this result change clinical practice?

Papers that advance understanding without changing practice are desk-rejected. Papers that are clinically interesting but don't have strong enough evidence to change guidelines are desk-rejected. Papers where the clinical consequence is real but narrow (one disease subtype, one demographic) may be redirected to a specialty journal.

NEJM's review process is tighter than most journals:

• Fewer reviewers: In almost all cases, two peer reviewers evaluate each submission

• Faster turnaround: NEJM says reviewers typically report within one to two weeks

• Statistical review: Once a manuscript moves to Revision status, most research manuscripts get at least one review by one of NEJM's five statistical consultants

• Focused review criteria: Reviewers assess clinical significance and evidence strength

The review is not a general scientific evaluation. It's specifically about whether the evidence supports a clinical practice change and whether the presentation is appropriate for a physician audience.

Fast desk rejection (1 week): The paper is good science but not practice-changing evidence. No reflection on quality.

Desk rejection with suggestion: The editor may suggest a specialty journal. This means the work has merit but not NEJM-level clinical impact.

First review round: SciRev authors report an average of 1.9 months (only 8 reports, read October 2026), so treat this as a rough guide.

Revision timing: NEJM publishes no standard revision window, so the decision letter sets the expectation for your paper. Multiple iterations of peer review, statistical review, and revision will most likely occur.

Before sending that inquiry, check which stage the portal label actually points to. Our New England Journal of Medicine under review guide walks through each status, from file intake to editor synthesis.

The useful signal in NEJM timing is not just speed. It is selectivity discipline. A very fast rejection usually means the paper did not clear the practice-changing threshold, not that the journal missed the science. A paper that enters review has already passed the main editorial question and is being tested for whether the claim is strong enough, broad enough, and concise enough for a physician audience.

That should change how authors prepare: tighten the clinical consequence early, remove side arguments, and make sure the main trial or cohort result can survive skeptical reading without long explanation.

It should also change how you handle revision planning. Tight revision timelines make sense only when the manuscript is already operationally clean. If key tables, subgroup logic, or limitations language are still unsettled before submission, the timeline becomes a liability rather than an advantage.

That is why NEJM timing rewards papers that are already clinically decisive before they enter the system.

For NEJM-targeted manuscripts, three patterns most consistently predict slow review at The New England Journal of Medicine (NEJM). Of manuscripts we screened in 2025 targeting NEJM and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: NEJM editors enforce practice-changing-evidence threshold in the first week; mechanistic papers without immediate clinical translation get desk-rejected.

Scope-fit ambiguity in the abstract. NEJM editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (clinical evidence that could change what a practicing clinician does tomorrow, not eventually). The named failure pattern: mechanistic papers without immediate clinical-translation framing get desk-screened within the first week. Check whether your abstract reads to NEJM's scope →

Methods package incomplete for the journal's reviewer pool. NEJM reviewers expect specific methodological detail. Trials missing the explicit pre-specified primary endpoint get extended methodology revision. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. A retracted paper in the reference list is hard to defend once an editor or reviewer notices it. Check whether your reference list is clean against Crossref + Retraction Watch →

Published NEJM review-time medians mask real variation. Desk rejections at NEJM (initial in-house review is typically completed in less than one week, per NEJM) pull the median down; papers that pass desk-screen and enter full peer review experience longer waits than the median suggests. The published median does not include acceptance-to-publication production time.

A NEJM desk-rejection risk check scores fit against the journal's editorial bar.